Fig 5.
Combinations of EGCG, a c-Met inhibitor and erlotinib synergistically block proliferation of H460 cells. In (A), H460 cells were pretreated with SU11274 at varying doses as indicated prior to stimulation with HGF 33 ng/ml. Lysates were subjected to PAGE and Western blotting with a phosphospecific antibody to the c-Met receptor. Tubulin was uses as a control for loading. In (B), H460 cells were cultured in the presence of EGCG at 10 or 20 μM, erlotinib at 2μM, or SU11274 at 5 μM alone or in combination. Viability was assessed after 72 h using a tetrazolium based assay and the data were expressed as described in the legend to Figure 1. In (C), H1975 cells were cultured in the presence of erlotinib at 2 μM, SU11274 at 5 μM, EGCG at 20 μM or combinations as noted. Viability was again assessed as described in the legend to Figure 1.
* P < 0.05 compared with FBS control.